Vera Therapeutics, Inc.
US ˙ NasdaqGM ˙ US92337R1014

SecurityVERA / Vera Therapeutics, Inc.
InstitutionAlps Advisors Inc
Latest Disclosed Ownership58,087 shares
Latest Disclosed Value $ 2,336,840
Alps Advisors Inc reports 10.87% increase in ownership of VERA / Vera Therapeutics, Inc.

On May 8, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 58,087 shares of Vera Therapeutics, Inc. (US:VERA) valued at $2,336,840 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 52,392 shares of Vera Therapeutics, Inc.. This represents a change in shares of 10.87% during the quarter. The current value of the position is $1,816,380 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F VERA THERAPEUTICS CL A 92337R101 58,087 5,695 10.87 2,337 -11.95 0.0101
2026-02-12 2025-12-31 13F VERA THERAPEUTICS CL A 92337R101 52,392 21,642 70.38 2,653 197.09 0.0155
2025-11-05 2025-09-30 13F VERA THERAPEUTICS CL A 92337R101 30,750 -3,691 -10.72 894 10.11 0.0050
2025-08-11 2025-06-30 13F VERA THERAPEUTICS CL A 92337R101 34,441 -12,071 -25.95 811 -27.39 0.0047
2025-04-30 2025-03-31 13F VERA THERAPEUTICS CL A 92337R101 46,512 -4,695 -9.17 1,117 -48.41 0.0065
2025-02-13 2024-12-31 13F VERA THERAPEUTICS CL A 92337R101 51,207 6,941 15.68 2,166 10.69 0.0137
2024-11-12 2024-09-30 13F VERA THERAPEUTICS CL A 92337R101 44,266 1,432 3.34 1,957 26.28 0.0131
2024-08-13 2024-06-30 13F VERA THERAPEUTICS CL A 92337R101 42,834 4,102 10.59 1,550 -7.25 0.0106
2024-05-14 2024-03-31 13F VERA THERAPEUTICS CL A 92337R101 38,732 8,512 28.17 1,670 259.91 0.0118
2024-02-14 2023-12-31 13F VERA THERAPEUTICS CL A 92337R101 30,220 -2,490 -7.61 465 3.57 0.0037
2023-11-14 2023-09-30 13F VERA THERAPEUTICS CL A 92337R101 32,710 175 0.54 448 -14.18 0.0037
2023-08-14 2023-06-30 13F VERA THERAPEUTICS CL A 92337R101 32,535 4,906 17.76 522 143.93 0.0045
2023-05-10 2023-03-31 13F VERA THERAPEUTICS CL A 92337R101 27,629 8,880 47.36 214 -40.88 0.0019
2023-02-14 2022-12-31 13F VERA THERAPEUTICS CL A 92337R101 18,749 4,005 27.16 363 15.29 0.0032
2022-11-14 2022-09-30 13F VERA THERAPEUTICS CL A 92337R101 14,744 -1,316 -8.19 314 43.38 0.0030
2022-08-15 2022-06-30 13F/A-1 VERA THERAPEUTICS CL A 92337R101 16,060 16,060 219 0.0021
2022-08-11 2022-06-30 13F VERA THERAPEUTICS CL A 92337R101 16,060 16,060 219 0.0021
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.